Monte Rosa Therapeutics Stock Technical Analysis
| GLUE Stock | USD 17.66 0.00 0.00% |
As of the 10th of March, Monte Rosa trades around 17.66 per share. Indicator dispersion currently includes Downside Deviation of 4.06, mean deviation of 4.03, and Risk Adjusted Performance of 0.0522. The evaluation incorporates historical dispersion and relative strength measures. Normalized comparisons highlight positioning versus competitors.
Monte Rosa Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Monte, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to MonteMonte Rosa's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Monte Rosa Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 33.17 | Strong Buy | 9 | Odds |
The summary for Monte Rosa Therapeutics includes current and past analyst recommendations. Average analyst consensus is included for context. Analyst target prices for Monte Rosa Therapeutics are typically set with a 12-month horizon and revised at each earnings cycle. Investors should compare Monte's current price to the consensus target to assess the implied upside or downside relative to the Street's view.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Investors evaluate Monte Rosa Therapeutics using market value and book value, each describing different facets of the business. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Market price responds to sentiment, liquidity, and macro shifts, so gaps can appear. Valuation work aligns these measures into a single context.
Value and price for Monte Rosa are related but not identical, and they can diverge across cycles. Context can include financial performance, operating efficiency, market trends, and peer comparisons. The quoted price is simply the exchange level where supply meets demand.
Monte Rosa 'What if' Analysis
Running a what-if backtest on Monte Rosa Therapeutics gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Monte Rosa's historical reward profile was stable enough to support the current thesis.
| 12/10/2025 |
| 03/10/2026 |
A 0.00 position in Monte Rosa initiated on December 10, 2025 and held to today would record 0.00 in aggregate gains. The change equals a 0.0% cumulative return in Monte Rosa on balance over a 90 day window.. Monte Rosa competes with or is related to Day One, Arvinas, Replimune, Theravance Biopharma, ArriVent BioPharma, Geron, and Vir Biotechnology. Peer context can support comparative analysis. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision... More
Momentum Range Indicators for Monte Rosa Signals
Upside/downside measures for Monte Rosa frame directional pressure and range behavior. The signals are presented as informational context for recent price movement.
| Downside Deviation | 4.06 | |||
| Information Ratio | 0.0543 | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | -6.69 | |||
| Potential Upside | 9.41 |
Volatility and Risk Indicators for Monte Rosa Signals
These indicators track Monte Rosa's volatility and return range dynamics. This view provides neutral context for risk and variability.| Risk Adjusted Performance | 0.0522 | |||
| Jensen Alpha | 0.3864 | |||
| Total Risk Alpha | 0.3889 | |||
| Sortino Ratio | 0.0952 | |||
| Treynor Ratio | -0.64 |
Mean reversion in Monte Rosa's is distinct from trend following. Where trend followers ride price momentum, mean reversion investors bet that extended moves will reverse once the underlying driver runs out of fuel.
Monte Rosa Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0522 | |||
| Market Risk Adjusted Performance | -0.63 | |||
| Mean Deviation | 4.03 | |||
| Semi Deviation | 3.75 | |||
| Downside Deviation | 4.06 | |||
| Coefficient Of Variation | 1795.5 | |||
| Standard Deviation | 7.12 | |||
| Variance | 50.7 | |||
| Information Ratio | 0.0543 | |||
| Jensen Alpha | 0.3864 | |||
| Total Risk Alpha | 0.3889 | |||
| Sortino Ratio | 0.0952 | |||
| Treynor Ratio | -0.64 | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | -6.69 | |||
| Potential Upside | 9.41 | |||
| Downside Variance | 16.52 | |||
| Semi Variance | 14.05 | |||
| Expected Short fall | -4.96 | |||
| Skewness | 4.05 | |||
| Kurtosis | 24.39 |
Monte Rosa Therapeutics Backtested Returns
Monte Rosa indicates a stable performance profile under the selected horizon. It has a Sharpe Ratio of 0.0363, evidencing risk-calibrated returns. We identified twenty-five technical indicators influencing the company's volatility profile. Please analyze metrics such as mean deviation of 4.03, risk-adjusted performance of 0.0522, and Downside Deviation of 4.06 to confirm variance-based stability. On a scale of 0 to 100, Monte Rosa holds a performance score of 2. The company shows a Beta (market volatility) of -0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Monte Rosa are expected to decrease at a much lower rate. During the bear market, Monte Rosa is likely to outperform the market. Please double-check Monte Rosa's potential upside, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Monte Rosa's current price movements will revert.
Auto-correlation | -0.46 |
Modest reverse predictability
Monte Rosa Therapeutics exhibits modest reverse predictability. Autocorrelation measures the degree of predictability between Monte Rosa time series from 10th of December 2025 to 24th of January 2026 and from 24th of January 2026 to 10th of March 2026. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of Monte Rosa Therapeutics may be projected. A serial correlation of -0.46 indicates that about 46.0% of current Monte Rosa price fluctuations can be explained by its historical price movements. Given that Monte Rosa Therapeutics has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.46 | |
| Spearman Rank Test | -0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 1.94 |
Technical analysis for Monte Rosa evaluates price and volume patterns over time. The model references moving averages, relative strength, and price correlation signals.
Monte Rosa Therapeutics Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Normalized Average True Range is used to analyze tradable apportunities for Monte Rosa Therapeutics across different markets.
Monte Rosa Therapeutics Price Indicators and Signals
Technical analysis of Monte Rosa evaluates price structure, momentum, and volatility clustering. Mean-reversion patterns can emerge after volatility spikes. We evaluate Monte Rosa through the lens of long-term portfolio construction and diversification efficiency.
Methodology
Unless otherwise specified, financial data for Monte Rosa Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Monte (USA Stocks:GLUE) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Technical and fundamental diagnostic scores are rule-based values computed from historical price and fundamental inputs.
Assumptions
The dataset for Monte Rosa Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Monte Rosa Therapeutics is covered by 8 analysts. 4 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Goldman Sachs, BMO Capital Markets, HSBC Global Research, Guggenheim Securities, Barclays, Oppenheimer & Co., Evercore ISI, Citigroup, among others. Updates may occur throughout the day.
Monte Rosa Technical Indicators
A technical review of Monte Rosa Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0522 | |||
| Market Risk Adjusted Performance | -0.63 | |||
| Mean Deviation | 4.03 | |||
| Semi Deviation | 3.75 | |||
| Downside Deviation | 4.06 | |||
| Coefficient Of Variation | 1795.5 | |||
| Standard Deviation | 7.12 | |||
| Variance | 50.7 | |||
| Information Ratio | 0.0543 | |||
| Jensen Alpha | 0.3864 | |||
| Total Risk Alpha | 0.3889 | |||
| Sortino Ratio | 0.0952 | |||
| Treynor Ratio | -0.64 | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | -6.69 | |||
| Potential Upside | 9.41 | |||
| Downside Variance | 16.52 | |||
| Semi Variance | 14.05 | |||
| Expected Short fall | -4.96 | |||
| Skewness | 4.05 | |||
| Kurtosis | 24.39 |
Monte Rosa March 10, 2026 Daily Trend Indicators
A technical review of Monte Rosa Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | 0.00 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 17.66 | ||
| Day Typical Price | 17.66 | ||
| Price Action Indicator | 0.00 |
Popular Tools for Monte Stock analysis
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |